Abstract:Objective: To observe the Shugan Liqi Zhixie Tang (SLZT) in treatment of 68 patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Method: One hundred and thirty-six cases with IBS-D were randomly divided into treatment group and control group, and each group had 68 cases. The treatment group was given SLZT, one dose/d, and they were used by oral and enema administration; the control group was given trimebutine maleate capsules, 100 mg/time, 3 times/d, and they were used by oral for 8 weeks. The symptoms severity were used by IBS scale table (IBS-BSS), and recorded the main digestive symptom score to evaluate the quality of life of patients, recorded Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) score and recorded the 3 months recurrent rate of follow-up period. Result: The total effective rate of the treatment group was 89.71% higher than 72.05% of the control group (P<0.05); total effective rate of the treaditional Chinese medicine syndromes in treatment group was 92.64% better than 70.58% of the control group (P<0.01); the IBS-BSS, HAMA, HAMD score of the treatment group were better than the control group (P<0.01), and IBS-QOL score was significantly higher and the control group (P<0.01); abdominal pain, bloating, stool frequency, stool shape and mucus score of the treatment group were better than the control group (P<0.01); the patients were followed up for 3 months, and the cumulative recurrence rate of the control group was 88.23% higher than 58.82% of the treatment group (P<0.01). Conclusion: SLZT in treatment of IBS-D can improve the clinical symptoms and psychological symptoms and improve the quality of life of patients, the clinical effect is significant, and the recurrence rate is low, which is worth to be applied in clinical.
